Table 1

Plasma DNA: diagnoses; quantitations; presence of T-cell DNA; and hypermethylation of CDKN2A promoter

PatientCancerDNA (ng/ml)T cellsaCDKN2Ab
C1Colorectal167
C2Angiosarcoma19NDc+
C3NSCLC100ND
C4Breast66
C5Breast134ND
C6SCLC33ND
C7Breast170ND
C8Breast83+
C9Ewing’s sarcoma60+
C10Breast20ND+
C11NSCLC84ND
C12Head and neck10ND+
C13Melanoma20ND+
C14Pancreas1200+
C15Colorectal67
C16Colorectal25NDND
C17Colorectal50ND
C18Breast38ND
C19Breast90
C20Pancreas48+
C21HCC84
C22Urothel168
C23Breast360+
T1NSCLC550+
T2Colorectal555+
T3Esophagus833+
T5Stomach500+
T6Colorectal980
T7Colorectal38ND
T8Colorectal34ND
  • a + or −, presence or absence, respectively, of T-cell DNA in plasma samples.

  • b +, hypermethylation of CDKN2A gene promoter; −, no hypermethylation detected.

  • c ND, not done; NSCLC, non-mall cell lung cancer; SCLC, small cell lung cancer; HCC, hepatocellular carcinoma.